Patents by Inventor Kyle Landskroner

Kyle Landskroner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of GM2 Gangliosidosis
    Publication number: 20250120958
    Abstract: The invention relates to a compound of formula (I), for use in treating GM2 gangliosidosis, specifically Sandhoff disease or Tay-Sachs disease. Specifically, the invention relates to a compound of formula (I) for use in increasing survival of a subject suffering from GM2 gangliosidosis, specifically Sandhoff disease or Tay-Sachs disease. The compound of formula (I) may also be used as an anti-inflammatory agent.
    Type: Application
    Filed: January 10, 2023
    Publication date: April 17, 2025
    Inventors: Jennifer Robin, Fritz Blatter, Robert Hett, Kyle Landskroner
  • Crystalline Forms of a Pharmaceutical Compound
    Publication number: 20250059137
    Abstract: The present invention relates to a crystalline form of compound (I) and a method of making the crystalline form of compound (I). The invention also provides pharmaceutical compositions comprising the crystalline form of compound (I). Furthermore, the invention relates to methods of using this crystalline form of compound (I) as a medicament and in the treatment of a disease involving abnormal levels of glucosylceramide and/or higher levels of glycosphingolipids.
    Type: Application
    Filed: August 30, 2024
    Publication date: February 20, 2025
    Inventors: Robert Hett, Fritz Blatter, Jennifer Robin, Kyle Landskroner
  • Crystalline forms of a pharmaceutical compound
    Patent number: 12116344
    Abstract: The present invention relates to a crystalline form of compound (I) and a method of making the crystalline form of compound (I). The invention also provides pharmaceutical compositions comprising the crystalline form of compound (I). Furthermore, the invention relates to methods of using this crystalline form of compound (I) as a medicament and in the treatment of a disease involving abnormal levels of glucosylceramide and/or higher levels of glycosphingolipids.
    Type: Grant
    Filed: October 1, 2021
    Date of Patent: October 15, 2024
    Assignee: Azafaros B.V.
    Inventors: Robert Hett, Fritz Blatter, Jennifer Robin, Kyle Landskroner
  • Crystalline Forms of a Pharmaceutical Compound
    Publication number: 20240287001
    Abstract: The present invention relates to a crystalline form of compound (I) and a method of making the crystalline form of compound (I). The invention also provides pharmaceutical compositions comprising the crystalline form of compound (I). Furthermore, the invention relates to methods of using this crystalline form of compound (I) as a medicament and in the treatment of a disease involving abnormal levels of glucosylceramide and/or higher levels of glycosphingolipids.
    Type: Application
    Filed: October 1, 2021
    Publication date: August 29, 2024
    Inventors: Robert Hett, Fritz Blatter, Jennifer Robin, Kyle Landskroner
  • Crystalline Forms of a Pharmaceutical Compound
    Publication number: 20230391724
    Abstract: The present invention relates to a crystalline form of compound (I) and a method of making the crystalline form of compound (I). The invention also provides pharmaceutical compositions comprising the crystalline form of compound (I). Furthermore, the invention relates to methods of using this crystalline form of compound (I) as a medicament and in the treatment of a disease involving abnormal levels of glucosylceramide and/or higher levels of glycosphingolipids.
    Type: Application
    Filed: October 1, 2021
    Publication date: December 7, 2023
    Inventors: Robert Hett, Fritz Blatter, Jennifer Robin, Kyle Landskroner